Jim Tananbaum: Healthcare Venture Capitalist

Jim Tananbaum is the chief executive and founder of Foresite Capital. Mr. Tananbaum founded Foresite Capital as a private equity firm that focusses solely in the healthcare industry. The firm identifies upcoming healthcare leaders and then provides them with capital, information and networks. Most companies who have received assistance from Foresite have achieved profitability.

Before founding Foresite Capital, Jim cofounded two healthcare investment firms and two prominent pharmaceutical companies. His first firm, GelTex, brought two drugs to the medical market at a cost of less than $80 million. The company was acquired in 1998 for $1.6 billion. At the time of the acquisition its leading drug Renagel was bringing in revenue in excess of $200 million. As of 2017 Renagel produces $1 billion in annual revenue. Mr. Jim Tananbaum was also a founder and CEO of Theravance, Inc. The company has respiratory franchise with GSK through the joint venture Innoviva. Innoviva has a market capitalization of $3.2 billion.

Early in his investment career Jim was a partner at Sierra Ventures where he assisted them in establishing their healthcare investment department. He was also a founder at Prospect Venture Partners 2 and 3. During his investment career Jim led numerous investments such as Amira Pharmaceuticals, which was acquired by Amerigroup, Jazz Pharmaceuticals and Healtheon. Jim used the wealth of knowledge and experience from his previous ventures to make a unique venture capital firm.

Jim Tananbaum attended college at Yale where he double majored in electrical engineering and computer science. He then obtained his MBA and MD from Harvard. He got his MS from MIT. Since a young age Jim has always been passionate about the marriage of computer science, mathematics and healthcare. During his studies he established productive and deep relationships with many leading academicians. He was also credits the following individuals for mentoring him Rick Levin (Yale), Valegos Roy (Merck and Theravence) and Whitesides George (Harvard). Jims experience has led him to believe that the world is about to enter a golden age where change and growth is driven by insights form data and deep learning. He envisions a future whereby blood and tissue from individuals is sequenced to prevent diseases before they even occur. You can visit his About.me page to know more about Jim.

See more: https://ideamensch.com/jim-tananbaum/